Gwendolyn K. Binder
Net Worth
Last updated:
What is Gwendolyn K. Binder net worth?
The estimated net worth of Dr. Gwendolyn K. Binder is at least $3,603,135 as of 19 Jan 2024. He owns shares worth $32,986 as insider, has earned $1,694,759 from insider trading and has received compensation worth at least $1,875,390 in Cabaletta Bio, Inc..
What is the salary of Gwendolyn K. Binder?
Dr. Gwendolyn K. Binder salary is $625,130 per year as Executive Vice President of Science & Technology in Cabaletta Bio, Inc..
How old is Gwendolyn K. Binder?
Dr. Gwendolyn K. Binder is 50 years old, born in 1975.
What stocks does Gwendolyn K. Binder currently own?
As insider, Dr. Gwendolyn K. Binder owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Cabaletta Bio, Inc. (CABA) | Executive Vice President of Science & Technology | 20,000 | $1.65 | $32,986 |
What does Cabaletta Bio, Inc. do?
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Gwendolyn K. Binder insider trading
Cabaletta Bio, Inc.
Dr. Gwendolyn K. Binder has made 16 insider trades between 2022-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 22,000 units of CABA stock on 19 May 2023. As of 19 Jan 2024 he still owns at least 20,000 units of CABA stock.
Cabaletta Bio key executives
Cabaletta Bio, Inc. executives and other stock owners filed with the SEC:
- Dr. David J. Chang M.D., M.P.H. (62) Chief Medical Officer
- Dr. Gwendolyn K. Binder (50) Executive Vice President of Science & Technology
- Dr. Steven A. Nichtberger (64) Co-Founder, Chairman, Chief Executive Officer & Pres